Tag:

Pfizer Covid

Pfizer raises 2025 profit outlook after strong Q2 results and cost cuts

Pfizer has raised its full-year 2025 adjusted earnings forecast after posting stronger-than-expected second-quarter results and making significant progress on cost-cutting. The pharmaceutical giant now anticipates earnings of $2.90 to $3.10 per share, up from its previous estimate of $2.80 to $3. It also reaffirmed its full-year revenue forecast of $61 billion to $64 billion.

05 Aug 2025-16:33
Japan grants emergency approval for Pfizer’s oral COVID-19 pill

10 Feb 2022-18:12
Pfizer estimates $54B from sale of COVID-19 vaccine, pills

08 Feb 2022-17:20
Britain to start rolling out Pfizer COVID pill next month

29 Jan 2022-10:34
EU regulator conditionally approves Pfizer's COVID-19 pill

27 Jan 2022-18:21
Sputnik V shows higher Omicron-antibody levels than Pfizer in preliminary study

21 Jan 2022-00:10
Pfizer CEO says omicron vaccine will be ready in March

10 Jan 2022-16:59
Pfizer, BioNTech partner up again to develop mRNA shingles vaccine

05 Jan 2022-18:11
FDA set to authorize Pfizer, Merck COVID-19 pills this week

21 Dec 2021-22:07
France approves Pfizer Covid-19 vaccine for all children aged 5-11

20 Dec 2021-19:16

Prev Next